Prevalence of anxiety or depression was investigated in 105 coronavirus disease 2019 (COVID-19) patients at 1 to 3 months from virological clearance by hospital anxiety and depression scale (HADS-A/D). 30% of patients displayed pathological HADS-A/D, 52.4% showed persistent symptoms. Pathological patients with HADS-A/D more commonly reported symptom persistence, even after adjustment for age, gender, and disease severity. Psychological assessments should be encouraged in COVID-19 patients' follow-up.
Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy / D. Tomasoni, F. Bai, R. Castoldi, D. Barbanotti, C. Falcinella, G. Mule, D. Mondatore, A. Tavelli, E. Vegni, G. Marchetti, A. d'Arminio Monforte. - In: JOURNAL OF MEDICAL VIROLOGY. - ISSN 0146-6615. - (2020). [Epub ahead of print] [10.1002/jmv.26459]
Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy
D. Tomasoni
Primo
;F. BaiSecondo
;R. Castoldi;D. Barbanotti;C. Falcinella;D. Mondatore;E. Vegni;G. MarchettiPenultimo
;A. d'Arminio MonforteUltimo
2020
Abstract
Prevalence of anxiety or depression was investigated in 105 coronavirus disease 2019 (COVID-19) patients at 1 to 3 months from virological clearance by hospital anxiety and depression scale (HADS-A/D). 30% of patients displayed pathological HADS-A/D, 52.4% showed persistent symptoms. Pathological patients with HADS-A/D more commonly reported symptom persistence, even after adjustment for age, gender, and disease severity. Psychological assessments should be encouraged in COVID-19 patients' follow-up.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jmv.26459(1).pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
537.05 kB
Formato
Adobe PDF
|
537.05 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
